# Becton, Dickinson and share price today (Becton, Dickinson and Company, BDX)

> Becton, Dickinson and Company's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. BDX · Healthcare · Medical Instruments & Supplies · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/bdx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $198.17 (+10.9% in a year)
- P/E: 59.5×, over 3.1 years
- Revenue (Jun 2026): $5.0 B
- Profit (Jun 2026): $377 M
- Operating margin: 15.7%
- ROE: 7%, FY25
- ROIC: 7.9%, against a 5.1% cost of capital: +2.8 points
- Profit that came in as cash: 213%, last 3 years

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Becton, Dickinson and share price today? Becton, Dickinson and Company's share price was $198.17 at the close on 3 November 2026. It has been stalling near its high for 14 weeks. That is 16.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between $143 and $210, and at that close it sat 82% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 15 weeks in a row. Over the last 10 years the share price moved +13% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Becton, Dickinson and pay? Becton, Dickinson and Company paid $4.19 per share over the last four reported quarters. The most recent declaration was $1.05 for Jun 2026. At today's price of $198.17 that is a yield of 2.11%, based on dividends already paid, not a forecast. ## Which stock lists is Becton, Dickinson and on? Becton, Dickinson and is on one of our US lists: S&P 500 companies. [S&P 500 companies](https://www.sectoralpha.in/sp-500-stocks)

## Is Becton, Dickinson and profitable? Becton, Dickinson and Company earned $377 M of net profit in the Jun 2026 quarter. Full-year FY25 profit was $1.7 B. Over 4 years profit has grown −4.3% a year on average. That is 7.6% of the quarter's revenue. The same quarter a year earlier earned $487 M. 1 of the last 8 reported quarters were loss-making. For the full year, FY25 profit was $1.7 B (−1.6% on the year before). ## How much revenue does Becton, Dickinson and make, and is it growing? Becton, Dickinson and Company reported $5.0 B of revenue in the Jun 2026 quarter. Over 4 years it has grown 3.4% a year on average. The last full year, FY25, came in at $21.8 B. The quarterly figures for FY25 do not add up to the full-year total on file, so those quarters are left out of the charts and sums. FY25 revenue was $21.8 B, +8.2% on the year before. ## How much of every $100 of sales does Becton, Dickinson and keep? Becton, Dickinson and Company's operating margin was 15.7% in the Jun 2026 quarter. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 11.0% and 16.8%. The latest quarter is within that range. Across 5 years it has been between 11.0% and 16.8%, and FY25's 16.8% is the highest of them. Why the margin moved: operating margin changed −0.2 percentage points on the year while gross margin changed +0.3 points. So the drop came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Becton, Dickinson and's profit turning into cash? Over the last 3 years, 213% of Becton, Dickinson and Company's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $3.4 B of operating cash against $1.7 B of profit. After $760 M of spending on assets, $2.7 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Becton, Dickinson and's cash go? Becton, Dickinson and Company does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.4 B on assets over the last 3 years. Averaged over those years that is 3.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $2.4 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Becton, Dickinson and's P/E ratio, and how does it compare with its own history? Becton, Dickinson and Company's P/E is 59.5×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −0.7% while the price moved +10.9%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved −8.5% a year; about −2.5% a year came from earnings growth and about −6.0 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Becton, Dickinson and business getting better or worse? Becton, Dickinson and Company's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 5 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Becton, Dickinson and earn on its capital? Becton, Dickinson and Company earned a ROE of 7% in FY25. That is up from a low of 6% in FY23. Its return on capital used (ROIC) is 2.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 7.7% net margin and 0.39× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 7.7% net margin × 0.39× asset turnover × 2.18× leverage (assets divided by equity) ≈ 6.5% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 7.9% − 5.1% = +2.8 percentage points. The 5.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does Becton, Dickinson and have too much debt? Becton, Dickinson and Company has total debt of $16.8 B against shareholder equity of $24.4 B as of Jun 2026, so its debt is 0.69× its equity. Year by year, that ratio went from 0.76 in FY21 to 0.79 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Becton, Dickinson and shareholding pattern? 3.3% of Becton, Dickinson and Company's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Becton, Dickinson and from balance-sheet trouble? For Becton, Dickinson and Company, the Z-score is 2.29. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.29 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Becton, Dickinson and rank in its industry? 51.0 out of 100, rank 9 of 30 in Medical Instruments & Supplies, with 71% of the evidence available. Becton, Dickinson and Company scores 51.0 out of 100 against the 30 companies it is compared with in Medical Instruments & Supplies, ranking 9. Relative strength against the index is 7.5%, and revenue and profit growth are weak. The four parts add up to the total exactly: 14.2 + 13.6 + 9.6 + 13.6 = 51. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Becton, Dickinson and compared with? Becton, Dickinson and ranks 9 of 30 Medical Instruments & Supplies companies on the 4-Factor Sector Score, with 51.0 out of 100. 1. [West Pharmaceutical Services, Inc.](https://www.sectoralpha.in/us/stocks/wst) WST · breaking out · Most evidence points up · 81% evidence 68.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.5/35 · Revenue 12.4% · Profit 15.8% · Operating margin change 1.6 points · 83% evidence Capital efficiency 20.6/25 · ROCE 21.2% · Operating margin 22.5% · 76% evidence Valuation 7.0/20 · P/E 44.9× · PEG 2.65 · 65% evidence Relative strength 17.7/20 · Lead over its industry 15.3% · Lead over S&P 500 26.8% · 1 year 50.2% · 100% evidence · 5 of 12 weeks ahead Exact sum: 23.5 + 20.6 + 7 + 17.7 = 68.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [LeMaitre Vascular, Inc.](https://www.sectoralpha.in/us/stocks/lmat) LMAT · turning · Evidence leans up · 81% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.7/35 · Revenue 11.5% · Profit 40.4% · Operating margin change 3.9 points · 83% evidence Capital efficiency 17.3/25 · ROCE 11.9% · Operating margin 29% · 76% evidence Valuation 14.0/20 · P/E 33.4× · PEG 0.86 · 65% evidence Relative strength 4.1/20 · Lead over its industry -25.2% · Lead over S&P 500 -17.1% · 1 year -7.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 26.7 + 17.3 + 14 + 4.1 = 62.1 · What this means: Earnings are strong; relative strength in its sector is -25.2% and the one-year return is -7.2%. 3. [Intuitive Surgical, Inc.](https://www.sectoralpha.in/us/stocks/isrg) ISRG · breaking out · Evidence leans up · 85% evidence 60.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.8/35 · Revenue 20.4% · Profit 7.7% · Operating margin change 3 points · 95% evidence Capital efficiency 21.4/25 · ROCE 22% · Operating margin 33.3% · 76% evidence Valuation 4.5/20 · P/E 48.6× · PEG 5.33 · 65% evidence Relative strength 8.0/20 · Lead over its industry -17.1% · Lead over S&P 500 -8.6% · 1 year -21.3% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.8 + 21.4 + 4.5 + 8 = 60.7 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 4. [AtriCure, Inc.](https://www.sectoralpha.in/us/stocks/atrc) ATRC · leader · Evidence leans up · 64% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.2/35 · Revenue 14% · Profit n/a · Operating margin change 10.8 points · 62% evidence Capital efficiency 6.1/25 · ROCE 2.2% · Operating margin 6.3% · 76% evidence Valuation 8.9/20 · P/E 134.3× · PEG n/a · 15% evidence Relative strength 19.6/20 · Lead over its industry 37.3% · Lead over S&P 500 49.6% · 1 year 88.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.2 + 6.1 + 8.9 + 19.6 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [ResMed Inc.](https://www.sectoralpha.in/us/stocks/rmd) RMD · breaking out · Evidence leans up · 81% evidence 57.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 9.8% · Profit 8.8% · Operating margin change -3 points · 83% evidence Capital efficiency 21.5/25 · ROCE 25.4% · Operating margin 30.9% · 76% evidence Valuation 10.2/20 · P/E 18.5× · PEG 1.91 · 65% evidence Relative strength 8.0/20 · Lead over its industry -14.3% · Lead over S&P 500 -5.8% · 1 year -9.7% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.8 + 21.5 + 10.2 + 8 = 57.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bausch + Lomb Corporation](https://www.sectoralpha.in/us/stocks/blco) BLCO · turning · Evidence leans up · 64% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 8.8% · Profit n/a · Operating margin change 6.8 points · 62% evidence Capital efficiency 7.2/25 · ROCE 3.4% · Operating margin 7.7% · 76% evidence Valuation 11.5/20 · P/E -18.5× · PEG n/a · 15% evidence Relative strength 16.3/20 · Lead over its industry 3.6% · Lead over S&P 500 14% · 1 year 28.8% · 100% evidence · 8 of 12 weeks ahead Exact sum: 21.4 + 7.2 + 11.5 + 16.3 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Merit Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/mmsi) MMSI · quiet · Evidence leans up · 81% evidence 55.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 10.3% · Profit 22.7% · Operating margin change 2.2 points · 83% evidence Capital efficiency 14.3/25 · ROCE 8.1% · Operating margin 14.5% · 76% evidence Valuation 12.7/20 · P/E 28.4× · PEG 1.22 · 65% evidence Relative strength 6.6/20 · Lead over its industry -7% · Lead over S&P 500 1.8% · 1 year -3.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22 + 14.3 + 12.7 + 6.6 = 55.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Kestra Medical Technologies, Ltd.](https://www.sectoralpha.in/us/stocks/kmts) KMTS · breaking out · Evidence leans up · 64% evidence 54.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.1/35 · Revenue 63.6% · Profit n/a · Operating margin change 27.5 points · 71% evidence Capital efficiency 3.4/25 · ROCE -48% · Operating margin -121.6% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 15.6/20 · Lead over its industry 4.2% · Lead over S&P 500 14.3% · 1 year 10.6% · 100% evidence · 9 of 12 weeks ahead Exact sum: 25.1 + 3.4 + 10 + 15.6 = 54.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. Becton, Dickinson and Company this page BDX · breaking out · Evidence leans up · 71% evidence 51.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 5.8% · Profit -40.6% · Operating margin change -1.4 points · 83% evidence Capital efficiency 13.6/25 · ROCE 7.6% · Operating margin 15.7% · 76% evidence Valuation 9.6/20 · P/E 44.3× · PEG n/a · 15% evidence Relative strength 13.6/20 · Lead over its industry -2% · Lead over S&P 500 7.5% · 1 year 11.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 14.2 + 13.6 + 9.6 + 13.6 = 51 · What this means: Relative strength against the index is 7.5%, and revenue and profit growth are weak. 10. [Repligen Corporation](https://www.sectoralpha.in/us/stocks/rgen) RGEN · leader · Evidence leans up · 74% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 16.5% · Profit n/a · Operating margin change 4.8 points · 62% evidence Capital efficiency 8.9/25 · ROCE 2.3% · Operating margin 9.3% · 76% evidence Valuation 3.7/20 · P/E 185.3× · PEG 8.54 · 65% evidence Relative strength 15.3/20 · Lead over its industry 5% · Lead over S&P 500 15% · 1 year 24.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.6 + 8.9 + 3.7 + 15.3 = 50.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Baxter International Inc.](https://www.sectoralpha.in/us/stocks/bax) BAX · quiet · Evidence leans up · 64% evidence 50.1 out of 100 Growth Capital Valuation Relative
12. [The Cooper Companies, Inc.](https://www.sectoralpha.in/us/stocks/coo) COO · basing · Evidence leans down · 85% evidence 49.5 out of 100 Growth Capital Valuation Relative
13. [STAAR Surgical Company](https://www.sectoralpha.in/us/stocks/staa) STAA · turning · Too little evidence to rank firmly · 58% evidence 49.2 out of 100 Growth Capital Valuation Relative
14. [Avantor, Inc.](https://www.sectoralpha.in/us/stocks/avtr) AVTR · leader · Evidence leans down · 71% evidence 48.7 out of 100 Growth Capital Valuation Relative
15. [Solventum Corporation](https://www.sectoralpha.in/us/stocks/solv) SOLV · losing its lead · Evidence leans down · 71% evidence 48.3 out of 100 Growth Capital Valuation Relative
16. [Alcon Inc.](https://www.sectoralpha.in/us/stocks/alc) ALC · turning · Evidence leans down · 61% evidence 47.0 out of 100 Growth Capital Valuation Relative
17. [Azenta, Inc.](https://www.sectoralpha.in/us/stocks/azta) AZTA · leader · Evidence leans down · 64% evidence 46.6 out of 100 Growth Capital Valuation Relative
18. [AptarGroup, Inc.](https://www.sectoralpha.in/us/stocks/atr) ATR · turning · Evidence leans down · 81% evidence 45.6 out of 100 Growth Capital Valuation Relative
19. [Align Technology, Inc.](https://www.sectoralpha.in/us/stocks/algn) ALGN · quiet · Evidence leans down · 81% evidence 44.1 out of 100 Growth Capital Valuation Relative
20. [Stevanato Group S.p.A.](https://www.sectoralpha.in/us/stocks/stvn) STVN · quiet · Evidence leans down · 81% evidence 43.7 out of 100 Growth Capital Valuation Relative
21. [Envista Holdings Corporation](https://www.sectoralpha.in/us/stocks/nvst) NVST · quiet · Too little evidence to rank firmly · 58% evidence 43.2 out of 100 Growth Capital Valuation Relative
22. [Teleflex Incorporated](https://www.sectoralpha.in/us/stocks/tfx) TFX · turning · Evidence leans down · 71% evidence 42.0 out of 100 Growth Capital Valuation Relative
23. [ICU Medical, Inc.](https://www.sectoralpha.in/us/stocks/icui) ICUI · quiet · Evidence leans down · 64% evidence 37.6 out of 100 Growth Capital Valuation Relative
24. [Medline Inc.](https://www.sectoralpha.in/us/stocks/mdln) MDLN · quiet · Too little evidence to rank firmly · 51% evidence 37.3 out of 100 Growth Capital Valuation Relative
25. [DENTSPLY SIRONA Inc.](https://www.sectoralpha.in/us/stocks/xray) XRAY · basing · Most evidence points down · 64% evidence 31.0 out of 100 Growth Capital Valuation Relative
26. [Warby Parker Inc.](https://www.sectoralpha.in/us/stocks/wrby) WRBY · quiet · Most evidence points down · 64% evidence 30.1 out of 100 Growth Capital Valuation Relative
27. [BioLife Solutions, Inc.](https://www.sectoralpha.in/us/stocks/blfs) BLFS · Too little evidence to rank firmly · 44% evidence 48.0 out of 100 Growth Capital Valuation Relative
28. [Pulse Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/plse) PLSE · leader · Too little evidence to rank firmly · 41% evidence 44.0 out of 100 Growth Capital Valuation Relative
29. [MiniMed Group, Inc.](https://www.sectoralpha.in/us/stocks/mmed) MMED · quiet · Too little evidence to rank firmly · 41% evidence 39.1 out of 100 Growth Capital Valuation Relative
30. [Alamar Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/almr) ALMR · turning · Too little evidence to rank firmly · 28% evidence 38.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Instruments & Supplies](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies), all 30 compared on one page. ## Which companies are close to Becton, Dickinson and in size? Becton, Dickinson and is the 2nd largest of 38 Medical Instruments & Supplies companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Intuitive Surgical, Inc. Just below it: Medline Inc., Alcon Inc., ResMed Inc., West Pharmaceutical Services, Inc. and Solventum Corporation. ### Medical Instruments & Supplies companies close in size

1. [Intuitive Surgical, Inc.](https://www.sectoralpha.in/us/stocks/isrg) $152.8 billion
2. Becton, Dickinson and Company $54 billion
3. [Medline Inc.](https://www.sectoralpha.in/us/stocks/mdln) $44.8 billion
4. [Alcon Inc.](https://www.sectoralpha.in/us/stocks/alc) $35.2 billion
5. [ResMed Inc.](https://www.sectoralpha.in/us/stocks/rmd) $31.9 billion
6. [West Pharmaceutical Services, Inc.](https://www.sectoralpha.in/us/stocks/wst) $28.4 billion
7. [Solventum Corporation](https://www.sectoralpha.in/us/stocks/solv) $14.4 billion

[All 38 Medical Instruments & Supplies companies, largest first](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies#all-companies)

### Companies close in size in other industries

1. [Delta Air Lines, Inc.](https://www.sectoralpha.in/us/stocks/dal) $54.6 billion · Airlines
2. [Realty Income Corporation](https://www.sectoralpha.in/us/stocks/o) $54.5 billion · REIT - Retail
3. Becton, Dickinson and Company $54.1 billion
4. [PACCAR Inc](https://www.sectoralpha.in/us/stocks/pcar) $54.1 billion · Farm & Heavy Construction Machinery
5. [Wheaton Precious Metals Corp.](https://www.sectoralpha.in/us/stocks/wpm) $54 billion · Gold

## What else do people ask about Becton, Dickinson and? ### What is Becton, Dickinson and's stock price today? Becton, Dickinson and Company's stock price is $198.17, +10.9% over the past year. The whole company is worth $54.0 B on the market. In the last 52 weeks it traded between $143 to $210; today it is 82% of the way up from the low, 16.8% above its 200-day average (as of 3 November 2026). ### What were Becton, Dickinson and's latest quarterly results? Becton, Dickinson and Company reported revenue of $5.0 B and net profit of $377 M for the Jun 2026 quarter. Earnings per share were $1.37. The operating margin was 15.7% (as of 3 November 2026). ### What is Becton, Dickinson and's market cap? Becton, Dickinson and Company's market capitalisation is $54.0 B at a stock price of $198.17. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Becton, Dickinson and performing? Becton, Dickinson and Company's share price has been stalling near its high for 14 weeks. Over the past 13 weeks it has done better than the S&P 500, for 15 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Becton, Dickinson and's stock price go up? This page does not forecast Becton, Dickinson and Company's stock price. What it shows instead: the stock price is $198.17, and it has been stalling near its high for 14 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Becton, Dickinson and in its business cycle? Becton, Dickinson and Company's FY25 operating margin was 16.8%, against a 5-year range of 11.0% to 16.8%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 15.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Becton, Dickinson and story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Becton, Dickinson and a stock worth studying right now? What the numbers show: Becton, Dickinson and Company's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- S&P 500 companies: https://www.sectoralpha.in/sp-500-stocks

This is research, not advice. We’re not SEBI-registered.